Stock comparison
BrainsWay
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BWAY
BrainsWay
Market cap
$592.27M
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BWAY | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 79B | HALO |
| Benjamin Graham | 70D | 83A | HALO |
| Philip Fisher | 57C | 65B | HALO |
| Peter Lynch | 52C | 53D | HALO |
| Joel Greenblatt | 46D | 40D | BWAY |
| Charlie Munger | 41D | 80C | HALO |
| Terry Smith | 52D | 84A | HALO |
Side-by-side metrics
| Metric | BWAY | HALO |
|---|---|---|
| Market cap | $592.27M | $8.1B |
| P/E (TTM) | 75.0x | 24.0x |
| EV/EBIT | 123.9x | 10.2x |
| ROIC (TTM) | 5.05% | 23.65% |
| Gross margin | 75.42% | 81.24% |
| Net margin | 13.5% | 23.13% |
| Revenue CAGR 5y | 15.42% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.1x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BWAY leads on
- Debt / Equity0.1xvs 1.0x+90%
HALO leads on
- Market cap$8.1Bvs $592.27M+93%
- EV/EBIT10.2xvs 123.9x+92%
- ROIC (TTM)23.65%vs 5.05%+79%
- P/E (TTM)24.0xvs 75.0x+68%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.